Nikhil Lalwani, President and Chief Executive Officer

Mr. Lalwani is ANI’s President and Chief Executive Officer and a member of ANI’s Board. Prior to joining ANI in September 2020, Mr. Lalwani worked at Cipla Ltd (NSE: CIPLA), a global pharmaceutical company, from May 2012 to August 2020 where he held positions of increasing responsibility, including CEO of Cipla USA, CEO of InvaGen, Head of US Strategy, M&A & Integration, and Head of Cipla’s Global Respiratory business. In these roles, Mr. Lalwani developed and executed multi-year strategic growth plans for key products and facilitated successful acquisitions as Cipla entered the specialty pharmaceutical space. Prior to Cipla, Mr. Lalwani was an Associate Partner with McKinsey & Company serving pharmaceutical and healthcare companies across the world, and an engineer with Medtronic. Mr. Lalwani holds a B.S. in Electrical Engineering from Georgia Institute of Technology and an M.B.A. from the Wharton School at the University of Pennsylvania.

Stephen P. Carey, Senior Vice President and Chief Financial Officer

Mr. Carey has been the Company’s Vice President, Finance and Chief Financial Officer since May 2016, and a Sr. Vice President since December 2020. From June 2007 to October 2015, Mr. Carey held various executive financial positions at Par Pharmaceutical Companies, Inc., including Senior Vice President, Controller and Principal Accounting Officer. Prior to that, Mr. Carey held various financial and accounting positions at Schering-Plough Corporation. Mr. Carey has over 25 years of experience as a financial executive, 20 of which are in the pharmaceutical industry. Mr. Carey began his career at PricewaterhouseCoopers. Mr. Carey graduated from Montclair State University with a B.S. degree in Accounting.

James G. Marken, Sr. Vice President, Operations and Product Development

Mr. Marken provides leadership for the production, engineering and logistics functions for the company's multi-site prescription drug, and potent compound facilities in Baudette, Minnesota. Mr. Marken brings over 20 years of pharmaceutical industry experience to his position. Prior to joining ANI Pharmaceuticals in 2007 as General Manager of the Minnesota facilities, he worked for Solvay Pharmaceuticals in various departments including Quality Control, Validation and Manufacturing. Mr. Marken holds a B.S. degree in Chemistry from Bemidji State University.

Christopher Mutz, Chief Commercial Officer and Head of Rare Diseases

Mr. Mutz brings deep experience in the successful commercialization of rare disease therapies, spending more than eight years with Alexion Pharmaceuticals (Nasdaq: ALXN). Most recently, as Vice President of the U.S. Neurology Business Unit, he was responsible for building and leading the successful launch of Soliris (eculizumab) for gMG and NMOSD in the United States. At Alexion, he also served as Vice President, U.S. Metabolic Business Unit and National Sales Director, U.S. Metabolic Business Unit. Prior to joining Alexion in 2011, Mr. Mutz served in commercial roles of increasing responsibility over the course of 11 years at Merck and Co. Mr. Mutz obtained his BA in Biology from the University of Virginia and his MBA from the Johnson Graduate School of Management at Cornell University.

Ori Gutwerg, Senior Vice President of Generics

Mr. Gutwerg is a seasoned leader and brings more than 17 years of experience building and driving growth in pharmaceutical companies. Most recently, Mr. Gutwerg served as Vice President, Head of U.S. Generics Rx at Taro Pharmaceuticals, overseeing a portfolio of nearly 300 generic and branded products. In that role, he drove double-digit top- and bottom-line growth, improved working capital through cost savings and efficiencies, rationalized the R&D pipeline and negotiated numerous business development deals to accelerate growth. Prior to joining Taro, he held positions with Xiromed US, Perrigo Pharmaceuticals, and Agis Group. Throughout his career, he has managed sales teams, built a commercial operations team, led M&A due diligence activities, and negotiated new business development and joint venture agreements. Mr. Gutwerg has a BS in Communications and Economics from The College of Management and an MBA from Tel Aviv University.